Mrs Sara Mazzuoccolo Switzerland

APR Applied Pharma Research SA
Head of Alliance & Sales 

Mr Francois MOLK Switzerland

TRB CHEMEDICA INT. SA
Sales, Licensing & Marketing Director 

Dr Michael Motz Switzerland

NETRIS PHARMA
CBO 

Dr Joseph O'Sullivan Switzerland

Glenmark Pharmaceuticals SA
VP and Head of Global BD&L for Innovative Products 

Mr Anil Okay Switzerland

Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, OTC and biosimilar products around the world.

A unique portfolio of high-quality and difficult-to-make products fuels our targeted growth strategy.

The company has commercial operations in 35 countries with 2,800 employees and operates five manufacturing and development hubs in the U.S., Romania, Korea and Taiwan.

Alvogen's product portfolio consists of a broad range of leading molecules for the treatment of conditions in the areas of oncology, cardiology, respiratory, Women Health, neurology and gastroenterology, in addition to a fast-growing portfolio of biosimilars and OTC products.  


Mr Anil Okay
Alvogen
LinkedIn logo Vice President Business Development B2B 

Dr Fabrice Paradies Switzerland

Debiopharm International SA
Director Industrial Business Develpment & Global Commercial Alliances 

Dr Roland Pfeiffer Switzerland

Vifor Pharma
Head of Commercial Development Europe 

Mr Adrian Pflugshaupt Switzerland

MergerMotives GmbH - The M&A Consulting Boutique

"Customized support for Mergers & Acquisitions, In- and Outlicensing, Business Development and other related areas".

We are a small and specialized M&A consulting boutique with a young and innovative mindset that is advising and supporting its clients in Mergers & Acquisitions, In- and Outlicensing, Business Succession, Business Development and other related areas. Our clients are companies from various industries all around the world that either do not have their own Business Development team or that need some additional temporary resources for their M&A team.

Mr Adrian Pflugshaupt
MergerMotives
LinkedIn logo Managing Partner 

Mr Gilbert Pfund Switzerland

Luye Pharma Group

Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The company has established R&D centers in China, the U.S. and the EU, with a robust pipeline of 30 drug candidates in China and more than 10 drug candidates overseas. The company currently has a number of new drugs and new formulations in the central nervous system and oncology therapeutic areas under study in the U.S. and the EU. Luye Pharma is a global cutting edge company in terms of research into new drug delivery technologies, such as microspheres, liposomes and transdermal drug delivery systems. The company is forward looking, with strategic development of innovative new compounds and antibodies, gene & cell therapies and smart formulations.

Luye Pharma has set up 7 manufacturing sites with over 30 production lines in total, establishing GMP quality management and international standard control systems. The company offers more than 30 products covering the 4 largest and fastest growing therapeutic areas — oncology, cardiovascular, metabolism and central nervous system, with business conducted in over 80 countries and regions around the world, including the largest pharmaceutical markets - China, the U.S., the EU and Japan, as well as fast growing emerging markets.

Luye Pharma
Senior Manager Business Development and Licensing 

Dr Marc Raber Switzerland

Mergers & Acquisitions

We are a deal broker and M&A advisory boutique that is specializing in transactions in the corporate sector of the pharmaceutical and healthcare industry and the consumer goods industry.

We support our clients in

  • Purchase and sale of companies and participations
  • Purchase and sale of brands and product portfolios
  • Business cooperations

We carry out targeted searches for transaction opportunities worldwide and support our clients in all phases of the M&A process.

Due to our long experience in this field and our continuously updated network of more than 40,000 strategic and financial investors worldwide we are able to quickly identify suitable investors and/or targets and complete transactions discreetly and reliably.

Dr Marc Raber
PMC Pharma Management Consultants GmbH
Managing Director